The changes include new CEOs for CTC Clinical Trial Consultants (CTC) and Toxicology Knowledge Team Sweden (TKT), and a new role as Chief Commercial Officer for CTC’s current CEO Anders Millerhovf. 

“I am proud of our internal talents and grateful for the opportunity to foster leadership through internal career development,” says Karin Meyer, CEO, CTR.

Anders Millerhovf – CCO of CTC and CTR

The largest company within the group, the full-service CRO CTC, has been led by CEO Anders Millerhovf since 2015. Millerhovf will now step into a new dual role as Chief Commercial Officer for CTC and CTR, focusing on driving customer relations and business development for CTC as well as the entire corporate group under CTR. Millerhovf, who holds an MSc in Medical Biology from Linköping University, co-founded CTC in 2011 and has thus been instrumental in leading CTC in becoming a market leader for early clinical trials in Northern Europe, states the company. 

“After ten years as CEO, I feel both proud and grateful for the journey we have made together. Moving into my new role as Chief Commercial Officer gives me the opportunity to continue contributing to both CTC and CTR in new ways,” says Millerhovf.

Suzanne Iverson Hemberg – CEO of CTC

Suzanne Iverson Hemberg, the current CEO of TKT, will become CEO of CTC. Iverson Hemberg brings experience from both the corporate and public healthcare sectors, having previously held Senior Director positions in Laboratory Medicine at Sahlgrenska University Hospital as well as principal scientific and middle management roles at AstraZeneca. She has a PhD in Pharmacology and Toxicology from the University of Toronto after which she undertook a postdoc in Molecular Toxicology at Karolinska Institutet. Iverson Hemberg will continue her involvement in TKT as a member of the board. 

“As the new CEO of CTC, I am looking forward to combining my passion for the science behind development of safe and effective therapeutics with my energy, drive and solid track record in leading in a complex environment,” says Iverson Hemberg.

Anna Steneholm – CEO of TKT

Anna Steneholm, CEO of TKT.

Anna Steneholm, who has worked as Senior Toxicology Consultant at TKT since 2022, will take the role as CEO of the company.

Steneholm holds a PhD in Toxicology from Karolinska Institutet, and has previously held senior roles within toxicology in the chemical and petroleum industry, for example with the trade organisation Concawe and Nynas.

“I look forward to our team’s continued contribution to the safety of pharmaceutical and chemical products, maintaining the same high quality, scientific curiosity, and integrity that’s the hallmark of the TKT team,” says Anna Steneholm.

These role changes will take effect during the last quarter of this year.